Glatiramer Acetate
- Generic Name
- Glatiramer Acetate
- Brand Names
- -
- Drug Type
- -
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Indication
用于治疗复发型多发性硬化症（MS/罕见病），包括成人临床孤立综合征、复发-缓解性疾病和活动性继发进行性疾病。
- Associated Conditions
- -
- Associated Therapies
- -
Asses the Anti-inflammatory Effects of Short Term Copaxone Therapy on Patients the Acute Decompensated Heart Failure
- Conditions
- Interventions
- First Posted Date
- 2023-08-22
- Last Posted Date
- 2023-08-22
- Lead Sponsor
- Hadassah Medical Organization
- Target Recruit Count
- 14
- Registration Number
- NCT06003972
- Locations
- 🇮🇱
Hadassah Ein Kerem medical center-hospital ,Cardiology Department, Jerusalem, Israel
A Window of Opportunity Trial of Intratumoral Injection of Copaxone® in Patients With Percutaneously Accessible Tumors
- Conditions
- Interventions
- First Posted Date
- 2019-06-11
- Last Posted Date
- 2023-05-19
- Lead Sponsor
- University of Kansas Medical Center
- Target Recruit Count
- 10
- Registration Number
- NCT03982212
- Locations
- 🇺🇸
University of Kansas Cancer Center - CRC, Fairway, Kansas, United States
🇺🇸The University of Kansas Cancer Center, Westwood Campus, Kansas City, Kansas, United States
🇺🇸University of Kansas Cancer Center, Kansas City, Kansas, United States
Investigating the Neuroprotective Effect of Cop-1 (Copaxone) in Acute Primary Angle Closure
- Conditions
- Interventions
- First Posted Date
- 2013-09-05
- Last Posted Date
- 2013-09-06
- Lead Sponsor
- Singapore Eye Research Institute
- Target Recruit Count
- 196
- Registration Number
- NCT01936129
- Locations
- 🇸🇬
Singapore Eye Research Institute, Singapore, Singapore
Comparison of 1.5T vs. 3T Protocols After Treatment With Glatiramer Acetate (GA)
- First Posted Date
- 2009-07-10
- Last Posted Date
- 2021-03-19
- Lead Sponsor
- University at Buffalo
- Target Recruit Count
- 12
- Registration Number
- NCT00937157
- Locations
- 🇺🇸
Jacobs Neurological Institute, Buffalo, New York, United States
Comparison of Bone Effects With Copaxone and Interferon in Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2007-06-25
- Last Posted Date
- 2014-01-22
- Lead Sponsor
- Nancy Hammond, MD
- Target Recruit Count
- 60
- Registration Number
- NCT00490906
- Locations
- 🇺🇸
General Clinical Research Center, Kansas City, Kansas, United States
🇺🇸University of Kansas Medical Center, Kansas City, Kansas, United States
A Combination Trial of Copaxone Plus Estriol in Relapsing Remitting Multiple Sclerosis (RRMS)
- Conditions
- Interventions
- First Posted Date
- 2007-03-23
- Last Posted Date
- 2016-06-16
- Lead Sponsor
- University of California, Los Angeles
- Target Recruit Count
- 158
- Registration Number
- NCT00451204
- Locations
- 🇺🇸
Western Institute for Biomedical Research, Salt Lake City, Utah, United States
🇺🇸University of Texas Southwestern, Dallas, Texas, United States
🇺🇸Dartmouth Medical School, Lebanon, New Hampshire, United States
Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2021-11-16
- Target Recruit Count
- 75
- Registration Number
- NCT00176592
- Locations
- 🇺🇸
New Jersey Medical School, Newark, New Jersey, United States
BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients
- Conditions
- Interventions
- First Posted Date
- 2004-12-16
- Last Posted Date
- 2008-12-19
- Lead Sponsor
- Bayer
- Target Recruit Count
- 2244
- Registration Number
- NCT00099502
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.